Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis

Author(s): Catalina Abad, James A. Waschek

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 10 , 2011

Become EABM
Become Reviewer
Call for Editor


Multiple sclerosis (MS) is a progressive neurodegenerative disease affecting myelin and axons, which is perpetuated by autoreactive lymphocytes and other inflammatory cell types. Because of the multifactorial nature of this disease, therapies targeting a single process may not be sufficient to halt its progression. VIP and PACAP are two neuropeptides shown to regulate multiple aspects of innate and adaptive immunity, and can also act independently on neural cells to promote their survival and regeneration. Animal studies have proven the efficacy of these peptides for the treatment of several models of neural inflammatory disorders, including those which, like MS, have major Th1/Th17 components. In this review, the immunomodulatory actions of VIP and PACAP will be discussed, with particular emphasis on their potential significance in MS.

Keywords: VIP, PACAP, multiple sclerosis, EAE, neuroimmunomodulation, neuropeptides, immunoprivilege, dexamethasone, lipopolysaccharide, ligand flagellin, orchestrate, microglia, granzyme B, tolerogenic, encephalomyelitis, erythroleukemia, mitogen, myelin, glatiramer acetate

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [1025 - 1035]
Pages: 11
DOI: 10.2174/138161211795589364
Price: $65

Article Metrics

PDF: 15